97 related articles for article (PubMed ID: 15114279)
1. Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada.
Sloka JS; Hollett PD; Mathews M
Med Sci Monit; 2004 May; 10(5):MT73-80. PubMed ID: 15114279
[TBL] [Abstract][Full Text] [Related]
2. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
[TBL] [Abstract][Full Text] [Related]
3. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
[TBL] [Abstract][Full Text] [Related]
4. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer.
Cerfolio RJ; Ojha B; Bryant AS; Raghuveer V; Mountz JM; Bartolucci AA
Ann Thorac Surg; 2004 Sep; 78(3):1017-23; discussion 1017-23. PubMed ID: 15337041
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
[TBL] [Abstract][Full Text] [Related]
6. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
Wang YT; Huang G
Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
[TBL] [Abstract][Full Text] [Related]
7. Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer.
von Haag DW; Follette DM; Roberts PF; Shelton D; Segel LD; Taylor TM
J Surg Res; 2002 Apr; 103(2):160-4. PubMed ID: 11922730
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of 18F-FDG PET/CT for lymph node staging in non-small-cell lung cancers.
Liu BJ; Dong JC; Xu CQ; Zuo CT; Le JJ; Guan YH; Zhao J; Wu JF; Duan XH; Cao YX
Chin Med J (Engl); 2009 Aug; 122(15):1749-54. PubMed ID: 19781319
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
[TBL] [Abstract][Full Text] [Related]
10. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
Quaia E; Tona G; Gelain F; Lubin E; Pizzolato R; Boscolo E; Bussoli L
Acta Radiol; 2008 Nov; 49(9):995-1004. PubMed ID: 18651256
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
[TBL] [Abstract][Full Text] [Related]
12. Mediastinal staging of non-small cell lung carcinoma using computed and positron-emission tomography.
Kiernan PD; Sheridan MJ; Lamberti J; Dicicco B; Wigton R; Hetrick V; Vaughan B; Graling P
South Med J; 2002 Oct; 95(10):1168-72. PubMed ID: 12425503
[TBL] [Abstract][Full Text] [Related]
13. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients.
Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Ohbayashi C; Sugimura K
J Magn Reson Imaging; 2007 Oct; 26(4):1071-80. PubMed ID: 17896365
[TBL] [Abstract][Full Text] [Related]
14. Assessing short-term effects and costs at an early stage of innovation: the use of positron emission tomography on radiotherapy treatment decision making.
Remonnay R; Morelle M; Pommier P; Giammarile F; Carrère MO
Int J Technol Assess Health Care; 2008; 24(2):212-20. PubMed ID: 18400125
[TBL] [Abstract][Full Text] [Related]
15. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer.
Yang W; Fu Z; Yu J; Yuan S; Zhang B; Li D; Xing L; Zhao D; Mu D; Sun X; Fang Y; Huang Y; Li W
Lung Cancer; 2008 Jul; 61(1):35-43. PubMed ID: 18177978
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer.
Meyers BF; Haddad F; Siegel BA; Zoole JB; Battafarano RJ; Veeramachaneni N; Cooper JD; Patterson GA
J Thorac Cardiovasc Surg; 2006 Apr; 131(4):822-9; discussion 822-9. PubMed ID: 16580440
[TBL] [Abstract][Full Text] [Related]
17. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
Scott WJ; Shepherd J; Gambhir SS
Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.
Alzahouri K; Lejeune C; Woronoff-Lemsi MC; Arveux P; Guillemin F
Clin Radiol; 2005 Apr; 60(4):479-92. PubMed ID: 15767106
[TBL] [Abstract][Full Text] [Related]
20. The optimality of different strategies for supplemental staging of non-small-cell lung cancer: a health economic decision analysis.
Søgaard R; Fischer BM; Mortensen J; Rasmussen TR; Lassen U
Value Health; 2013; 16(1):57-65. PubMed ID: 23337216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
